Latest News
BrightFocus-funded researchers discover a potential new treatment approach for Alzheimer’s - restoring the function of regulatory T cells (Tregs) to control the body’s immune response and suppress Alzheimer’s-associated brain inflammation.
Press release on a new Alzheimer’s drug which shows promising results to slow disease progression.
Research suggests that changes to circulation and density of blood vessels in the eye may signal a risk of dementia and can be used as a screening tool for Alzheimer’s disease.
BrightFocus Foundation, a premier source of private research funding to defeat Alzheimer’s disease, macular degeneration, and glaucoma, today announced the addition of Sharyn Rossi, PhD, to its senior staff as the organization’s new Director of Scientific Programs, Neuroscience.
The WHAM! (Women’s Health Access Matters!) Investigators Fund today announced $100,000 in support from BrightFocus Foundation for sex and gender-specific research to advance women’s brain health.
In animal experiments, scientists document that the APOE4 allele impacts cell bioenergetics in the entorhinal cortex, a critical brain region first damaged in Alzheimer’s disease (AD).
Scientists describe how the protein tau is modified over four decades as Alzheimer’s develops and progresses.
New partnerships with BrightFocus Foundation and CURE will promote research, clinical trials in neurology practices nationwide
BrightFocus Foundation mourns the recent passing of Peter Davies, PhD. A globally-recognized leader in research on Alzheimer’s and related dementia, Dr. Davies served on our Scientific Review Committee for this field for 11 years, including six years as its chair.
In partnership with BrightFocus Foundation, the Medical Technology Enterprise Consortium (MTEC) today announced a request for proposals for research that will enable the advancement of candidate drugs for the treatment of repeated mild traumatic brain injury (mTBI).